Product image of Icatibant Viatris (Icatibant) supplied by GNH India

Icatibant Viatris

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Viatris (Icatibant)

Icatibant, the active ingredient in Icatibant Viatris, is a bradykinin B2 receptor antagonist presented as a sterile subcutaneous injection for subcutaneous use. It selectively blocks bradykinin‑mediated vasodilation and vascular permeability, providing rapid relief of swelling during acute hereditary angioedema attacks in diagnosed patients.

GNH India supplies Icatibant Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Manufacturer / TM Owner

Viatris Sante

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is used to treat hereditary angioedema by targeting the bradykinin pathway.

  • Hereditary angioedema type I: provides rapid reduction of swelling during acute attacks.
  • Hereditary angioedema type II: alleviates symptoms of sudden edema in affected individuals.
  • Hereditary angioedema with normal C1‑INH: offers prompt relief of attack‑related swelling.

How It Works

  • Icatibant acts as a selective, competitive antagonist of the bradykinin B2 receptor. By binding to this G‑protein‑coupled receptor, it prevents bradykinin from inducing vasodilation and increasing vascular permeability, which are key contributors to the edema seen in hereditary angioedema. The blockade results in rapid cessation of swelling and associated pain during an acute episode.

Side Effects

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or erythema: localized skin reddening.
  • Swelling at injection site: transient increase in local tissue volume.
  • Nausea: occasional feeling of queasiness.
  • Headache: mild to moderate head pain.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Hypersensitivity reactions: rash, urticaria, or anaphylaxis.
  • Severe angioedema: unexpected swelling of face, lips, or airway.
  • Hypotension: marked drop in blood pressure requiring medical attention.
  • Thrombocytopenia: low platelet count observed in laboratory tests.
  • Infection at injection site: signs of cellulitis or abscess formation.
  • Severe headache or migraine: persistent, intense head pain.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety measures.

  • Confirm diagnosis: ensure the patient has a confirmed hereditary angioedema diagnosis.
  • Monitor hypersensitivity: watch for signs of allergic reaction at the injection site.
  • Avoid in known hypersensitivity: do not administer to patients with documented allergy to icatibant or its excipients.
  • Pregnancy: safety not established; weigh potential benefits against risks.
  • Breastfeeding: unknown excretion; consider alternatives.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with other medicines that influence bradykinin pathways or hemodynamics.

Major Interactions (Avoid)

  • ACE inhibitors: concurrent use may increase bradykinin levels and worsen angioedema.
  • Neprilysin inhibitors: may elevate bradykinin and reduce efficacy of icatibant.

Moderate Interactions (Monitor Closely)

  • Estrogen‑containing oral contraceptives: may increase frequency of HAE attacks, monitor patient response.
  • NSAIDs: can exacerbate swelling in some patients, observe for increased symptoms.
  • Other B2 receptor antagonists: concurrent use may lead to additive effects, adjust therapy as needed.

Frequently Asked Questions

Icatibant Viatris is used to treat acute attacks of hereditary angioedema (HAE). It works by blocking the bradykinin B2 receptor, which helps stop the rapid swelling that characterises an HAE episode.

Icatibant is a selective competitive antagonist of the bradykinin B2 receptor. By binding to this receptor, it prevents bradykinin from causing vasodilation and increased vascular permeability, thereby reducing the swelling and pain associated with an HAE attack.

The dose of Icatibant Viatris is determined by the prescribing healthcare professional based on the patient’s condition, weight, and clinical response. The prescriber will provide specific instructions on the amount and frequency of administration.

Safety data for icatibant in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and it is not known whether the drug is excreted in breast milk. Use only if the potential benefit justifies the potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other therapies such as C1‑esterase inhibitor concentrates replace the deficient protein, and newer monoclonal antibodies target different pathways. Icatibant offers a rapid, subcutaneous option for acute attacks, while other agents may be administered intravenously or have different dosing schedules.

Icatibant Viatris should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If the temperature rises above the recommended range, discard the product.

Icatibant Viatris is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver. The site should be rotated to minimise local irritation.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe angioedema affecting the airway, marked hypotension, and rare cases of thrombocytopenia. Patients should be monitored closely after the first dose, and any signs of severe reaction require immediate medical attention.

Icatibant should not be used in individuals with a known hypersensitivity to icatibant or any of its excipients. Caution is advised for patients with uncontrolled cardiovascular disease, severe renal or hepatic impairment, and for pregnant or breastfeeding women where the benefit‑risk balance is uncertain.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT